CAV članku se razpravlja o zaskrbljenosti zaradi odobritve zdravila, ki temelji na izmišljenih podatkih, ki dvigujejo vprašanja o regulativnem nadzoru in integriteti farmacevtskih odobritev.
Ocena pristranskosti (Progresivno): Članek kritizira regulativni proces in izraža zaskrbljenost zaradi varnosti pacientov, kar kaže na sistemske pomanjkljivosti pri nadzoru.
Zakaj te ocene (Dejstva 65 · Objektivnost 45): The article makes strong allegations about a drug being approved on fake data but lacks specific evidence or citations to support these claims. It appears to present a narrative without sufficient detail, which lowers both factual accuracy and objectivity. The tone is critical and suggests bias with
